Vol 9, No S1 (2020)

Nowadays the use of anxiolytics is common in the medical practice all over the world. According to statistics, between 3.5% and 11.7% percents of the whole population of the world use anxiolytics to treat anxiety, insomnia, alcohol withdrawal, seizure and panic disorder as well as for conscious sedation and as a muscle relaxant. At the same time, it is well known that anxiolytics may cause strong side effects. Use of one the most widespread class of anxiolytics, Benzodiazepines, is usually associated with drowsiness, confusion, dizziness, trembling, incoordination, vision problems, grogginess and depression. They also may have deleterious effects on memory and cognition, and may be associated with an increased risk of Alzheimer's disease. In addition to the above negative effects, numerous studies have evaluated the association of hypnotics and anxiolytics use with mortality risk. That is why the current situation of widespread use of anxiolytics seems now as a cause for alarm. The situation becomes even more dangerous since anxiolytics cause strong addiction, while the abuse of these medicines increases the risk of mortality. Aforementioned illustrates well why study of the anxiolytic addiction is one of the actual topics in modern pharmacy.

Currently alcoholism and alcoholics are increasing day by day and now every country should take account for it as more youth are engaged in such situation.

Doping scandals actively involved in the press with the participation of athletes from different sports and countries update the issue of awareness of athletes about the risk of taking prohibited drugs. The pursuit of sporting achievements at the price of using doping agents is unacceptable from a moral and ethical point of view of pure sport and is unsafe for the health of an athlete in general.

Some countries legalize cannabis drug class for chronically ill patients. Canada and the Netherlands have government programs in which specialized companies supply with quality controlled cannabis herb. In the United States of America, 23 states and Washington, DC (May 2015), laws allowing medical use of cannabis have enacted; other countries have similar laws [1]. In the wake of the legalization of these substances, their properties should be considered and pharmacological characteristics should be given to them.

Nowadays treatment of drug addiction consists of abstinence from the abused substance and symptomatic therapy of “withdrawal syndrome”. Knowing pathogenesis of addiction it is possible to find new therapeutic targets for pharmacological interaction. Endocannabinoid system (ECS) is considered to be one of them.

Many people think that the frequent use of vasoconstrictive drops will not cause an addiction. Is that right?